HPV treatment with vaginal suppositories for mild cervical changes
Part of Cancer, Infections, Women’s health & pregnancy clinical trials.
This study tests a new vaginal medication (Dysplasix) to treat mild cervical cell changes caused by high-risk HPV. The goal is to see if this treatment can help your body clear the virus and prevent these changes from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 65 years old
- You have high-risk HPV confirmed by a recent test
- You have mild cervical cell abnormalities (ASCUS or LSIL) on a Pap test
- You can self-insert a vaginal suppository correctly
- You have a healthy immune system and are not pregnant
- You agree to use contraception and avoid HPV vaccination during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether artesunate vaginal inserts can help treat high-grade abnormal cells on the cervix (CIN2/3). It’s meant for adults who have a confirmed high-grade precancer change and can use birth control during the study.
This Phase 1 study tests FluBHPVE6E7, a new treatment designed to help the immune system respond to HPV16. It mainly checks safety and the best dose, and may help your body clear or control HPV over time.
This trial tests whether a supplement containing green tea extract, folic acid, vitamin B12, and hyaluronic acid can help clear HPV from the cervix. It's for people with a low-grade cervical lesion who have had HPV for a while.
This early (Phase 1) study tests a new treatment for people with long-lasting mild abnormal Pap test results (ASC-US or LSIL) who also have HPV16 found on testing. It aims to find out whether the treatment can be given safely and may affect the HPV and abnormal cell changes.
This study follows women with an early abnormal cervix cell change (CIN2/CIN2-3) to see how HPV DNA “integration” relates to whether the condition improves or worsens. It may help doctors better predict prognosis and guide safer monitoring, especially if you want to become pregnant.
This trial tests a light-activated drug (ALA-PDT) to treat low-grade cervical changes caused by HPV 16 or 18. It may help clear the virus and prevent progression to more serious disease.
Hear when a new HPV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.